UGT1A1 Gene Variations and Irinotecan Treatment in Colorectal Cancer Patients
Author Information
Author(s): Marcuello E, Altés A, Menoyo A, del Rio E, Gómez-Pardo M, Baiget M
Primary Institution: Hospital de la Santa Creu i Sant Pau
Hypothesis
The study investigates the influence of UGT1A1 polymorphism on toxicity, response rate, and overall survival in patients with metastatic colorectal cancer treated with irinotecan.
Conclusion
The UGT1A1*28 genotype is significantly associated with severe diarrhoea in patients treated with irinotecan.
Supporting Evidence
- Patients with the UGT1A1*28 genotype had a higher incidence of severe diarrhoea.
- The study included 95 patients with metastatic colorectal cancer.
- Statistical analysis showed significant relationships between genotype and toxicity.
Takeaway
This study found that some people have a gene variation that makes them more likely to get sick from a cancer treatment called irinotecan.
Methodology
The study involved 95 patients with metastatic colorectal cancer undergoing irinotecan-based chemotherapy, with UGT1A1 genotyping and analysis of clinical outcomes.
Potential Biases
Potential bias in patient selection and reporting of adverse effects.
Limitations
The study may not generalize to all populations due to its focus on a specific genetic variant in a predominantly Caucasian cohort.
Participant Demographics
60% men, median age 68 years, predominantly Caucasian.
Statistical Information
P-Value
0.001
Confidence Interval
0.28–0.41
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website